Integra LifeSciences Medical Director Highlights Commitment to Transformational Patient Care

Reuters

Dec 05

Integra LifeSciences Medical Director Highlights Commitment to Transformational Patient Care

Integra LifeSciences Holdings Corporation recently featured a Q&A with Dr. Malachy Asuku, Medical Director for Wound Reconstruction and Care within Medical Affairs. Dr. Asuku discussed his transition from a reconstructive surgeon to his current leadership role, highlighting his commitment to science-driven innovation and evidence generation. He emphasized Integra's new purpose-Restoring Lives-and its vision to advance transformational care, deliver impactful innovation, and enrich life moments for patients. Dr. Asuku also shared personal insights, including his passion for family, travel, and sports, and described his role as dynamic and purpose-driven, involving clinician engagement and cross-functional collaboration to advance the company's priorities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Integra LifeSciences Holdings Corporation published the original content used to generate this news brief on December 05, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2589081370"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2589081370\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2589081370?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-05 22:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589081370","market":"us","top_or_hot":-1,"title":"Integra LifeSciences Medical Director Highlights Commitment to Transformational Patient Care","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Integra LifeSciences Medical Director Highlights Commitment to Transformational Patient Care\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Integra LifeSciences Holdings Corporation recently featured a Q&amp;A with Dr. Malachy Asuku, Medical Director for Wound Reconstruction and Care within Medical Affairs. Dr. Asuku discussed his transition from a reconstructive surgeon to his current leadership role, highlighting his commitment to science-driven innovation and evidence generation. He emphasized Integra's new purpose-Restoring Lives-and its vision to advance transformational care, deliver impactful innovation, and enrich life moments for patients. Dr. Asuku also shared personal insights, including his passion for family, travel, and sports, and described his role as dynamic and purpose-driven, involving clinician engagement and cross-functional collaboration to advance the company's priorities.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Integra LifeSciences Holdings Corporation published the original content used to generate this news brief on December 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Integra LifeSciences Medical Director Highlights Commitment to Transformational Patient Care</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntegra LifeSciences Medical Director Highlights Commitment to Transformational Patient Care\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-05 22:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Integra LifeSciences Medical Director Highlights Commitment to Transformational Patient Care\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Integra LifeSciences Holdings Corporation recently featured a Q&amp;A with Dr. Malachy Asuku, Medical Director for Wound Reconstruction and Care within Medical Affairs. Dr. Asuku discussed his transition from a reconstructive surgeon to his current leadership role, highlighting his commitment to science-driven innovation and evidence generation. He emphasized Integra's new purpose-Restoring Lives-and its vision to advance transformational care, deliver impactful innovation, and enrich life moments for patients. Dr. Asuku also shared personal insights, including his passion for family, travel, and sports, and described his role as dynamic and purpose-driven, involving clinician engagement and cross-functional collaboration to advance the company's priorities.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Integra LifeSciences Holdings Corporation published the original content used to generate this news brief on December 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL1mp5Wk:1","article_id":"2589081370","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589081370","pubTimestamp":1764946477,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Integra LifeSciences Holdings Corporation recently featured a Q&A with Dr. Malachy Asuku, Medical Director for Wound Reconstruction and Care within Medical Affairs. Dr. Asuku discussed his transition from a reconstructive surgeon to his current leadership role, highlighting his commitment to science-driven innovation and evidence generation. He emphasized Integra's new purpose-Restoring Lives-and its vision to advance transformational care, deliver impactful innovation, and enrich life moments for patients. Dr. Asuku also shared personal insights, including his passion for family, travel, and sports, and described his role as dynamic and purpose-driven, involving clinician engagement and cross-functional collaboration to advance the company's priorities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and sh","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","IART":"英特格拉生命科学"},"translate_title":"Integra LifeSciences医疗总监强调对转型患者护理的承诺","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IART":0.9},"content_text":"Integra LifeSciences Medical Director Highlights Commitment to Transformational Patient Care\n    \n\n        Integra LifeSciences Holdings Corporation recently featured a Q&A with Dr. Malachy Asuku, Medical Director for Wound Reconstruction and Care within Medical Affairs. Dr. Asuku discussed his transition from a reconstructive surgeon to his current leadership role, highlighting his commitment to science-driven innovation and evidence generation. He emphasized Integra's new purpose-Restoring Lives-and its vision to advance transformational care, deliver impactful innovation, and enrich life moments for patients. Dr. Asuku also shared personal insights, including his passion for family, travel, and sports, and described his role as dynamic and purpose-driven, involving clinician engagement and cross-functional collaboration to advance the company's priorities.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Integra LifeSciences Holdings Corporation published the original content used to generate this news brief on December 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}